The fact that aminoglycoside antibiotics can produce ototoxicity has been well established in both humans and experimental animals. The ototoxicity can take the form of damage to the auditory system (80) or the vestibular system (9, 31, 41, 70, 71) or both. This ototoxicity results in the destruction of the sensory hair cells in the cochlea and vestibular labyrinth. The first report of the clinical efficacy of the first aminoglycoside antibiotic, streptomycin, described the problem of hearing loss and dizziness resulting from the drug (39) .
Despite the vast amount of knowledge that has accumulated about the ototoxicity of this group of drugs, as evidenced from the large number of review articles about their ototoxicity (2-4, 11, 15, 18, 23, 24, 28, 36, 43, 46, 51-54, 57, 59, 62, 69, 74, 75, 87, 89, 90, 92, 93) , the incidence of hearing loss resulting from the aminoglycoside antibiotics in humans remains controversial. In like fashion, the question as to whether one aminoglycoside antibiotic is more or less likely to result in ototoxicity than another is in dispute.
The question as to the incidence of ototoxicity originates with the discrepancy between the clinical observations that very few of the patients receiving these drugs complain of developing a hearing loss and the reported incidence of ototoxicity of up to 41% in studies in which auditory thresholds were obtained (77) . There are two reasons for this discrepancy. The first relates to the fact that aminoglycoside antibiotics affect high-frequency hearing earlier than they affect low-frequency hearing (6, 16, 17, 22, 42, 49, 60, 67, 73, 88) . Hearing losses at higher frequencies are detectable audiometrically well before they have become severe enough to involve the speech frequency range, in which they can be detected by the patient. These frequencies are comparatively low when you consider that normal hearing frequencies are as high as 20 kHz. To understand speech, we rely greatly on our hearing at lower frequencies, from 0.3 through 3 kHz, which are affected only with very extensive aminoglycoside damage. Furthermore, even when the speech frequency range becomes involved, the hearing loss must be 25 to 30 dB before the patient notices much, or even arty, change in hearing. Most conventional audiometers test frequencies at 8 kHz and below, so that most of the observations are limited to this frequency range. Therefore, patients are very unlikely to complain of having any loss of hearing, even if asked, until considerable damage has been done (47, 63) . In cases in which the only damage occurs at frequencies above 8 kHz, it will not be detected, because most audiometers only test frequencies at 8 kllz and below.
Patients who have a hearing loss from 4 through 8 kHz often have difficulty understanding speech; however, the difficulty is not often recognized (47) . For such as an individual hospital room. Even in rather noisy environments the patient will still hear a word every time a word is spoken. The problem is that the word heard is not always the word spoken. This makes it difficult to carry on meaningful conversations in noisy surroundings. The time lag between the termination of aminoglycoside antibiotic therapy, when the patient is in a relatively quiet hospital, and the time that the patient would experience the problem of understanding speech in a noisy work environment can be considerable, so that the hearing difficulty, even if noticed, is not often associated with the drug treatment.
The second reason for the discrepancy between the clinical and experimental incidences of aminoglycoside antibiotic-induced ototoxicity has to do with the established criteria for ototoxicity. Most studies consider ototoxicity to have occurred if at any time after a base-line audiogram has been obtained an increase occurs in the auditory threshold of 15 dB or more at any two frequencies (38, 45, 52, 53, 55, 58, 61, 72) or 20 dB at one or more frequencies (5, 21, 25, 27) . Some investigators consider a 15-dB or greater change at any frequency to represent ototoxicity (4, 29, 40, 50, 76, [80] [81] [82] [83] 94) , and others use some combination of criteria (10, 32, 33, 66) . The basis for accepting a 15-dB change in threshold as a meaningful change is that it is standard procedure to use 5-dB steps in sound intensity when obtaining auditory thresholds. Experimental error allows a +5-dB discrepancy between audiograms. Thus, if the base-line audiogram had a -5-dB error and the subsequent audiogram had a +5-dB error the difference between the two audiograms would be 10 dB. A 10-dB discrepancy between audiometric thresholds would be considered normal. The next larger change recorded would be an additional 5-dB step, so that a 15-dB change would be the smallest change that would be greater than the inherent error of the method. Some investigators do not report the criteria they use to determine if a change in the auditory threshold has occurred (64, 68, (84) (85) (86) . The problem of not having a reliable, universally agreed-upon standard for the definition of drug-induced ototoxicity has been pointed out by Guay (34) (20) . Of Bryan (14) showed that changes of 17 to 20 dB at some frequencies must occur before statistical significance reaches the 5% confidence level between repeat audiograms. In that study the subjects were not sick and were not taking any drugs, so it is possible that in sick people even Although the evidence for the ototoxicity of aminoglycoside antibiotics is overwhelming, the incidence of this effect in humans is still in doubt. The principal factor preventing reliable estimates of this incidence has been the lack of adequate technology for audiological testing of these patients. This includes the lack of availability of high-frequency testing equipment and the lack of development of statistically significant standards of hearing loss in these patients. From a historical perspective, another factor which may confound comparisons between older and more recent data is the progressive change in the management of patients on these drugs. Today patients receiving aminoglycoside antibiotics are closely monitored, and dosing schedules are changed to match changes in their renal elimination of the drugs. These changes in treatment have been the result of the development of reliable and rapidly performed quantitations of aminoglycoside antibiotic concentrations in blood. 
